These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31780963)

  • 41. Validation of the Yale-Brown Obsessive-Compulsive Severity Scale in African Americans with obsessive-compulsive disorder.
    Williams MT; Wetterneck CT; Thibodeau MA; Duque G
    Psychiatry Res; 2013 Sep; 209(2):214-21. PubMed ID: 23664665
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Congruence and discrepancy between self-rated and clinician-rated symptom severity on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) before and after a low-intensity intervention.
    Hauschildt M; Dar R; Schröder J; Moritz S
    Psychiatry Res; 2019 Mar; 273():595-602. PubMed ID: 30716599
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of adjunctive low-frequency repetitive transcranial magnetic stimulation therapy over the left dorsolateral prefrontal cortex in patients with obsessive-compulsive disorder refractory to medical treatment:A double-blind, randomized clinical trial.
    Jahanbakhsh G; Alireza Haji Seyed Javadi S; Majidi M; Khademi M; Karimi R
    Asian J Psychiatr; 2023 Feb; 80():103384. PubMed ID: 36565659
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
    Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
    J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Defining clinical severity in adults with obsessive-compulsive disorder.
    Storch EA; De Nadai AS; Conceição do Rosário M; Shavitt RG; Torres AR; Ferrão YA; Miguel EC; Lewin AB; Fontenelle LF
    Compr Psychiatry; 2015 Nov; 63():30-5. PubMed ID: 26555489
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gamma ventral capsulotomy for obsessive-compulsive disorder: a randomized clinical trial.
    Lopes AC; Greenberg BD; Canteras MM; Batistuzzo MC; Hoexter MQ; Gentil AF; Pereira CA; Joaquim MA; de Mathis ME; D'Alcante CC; Taub A; de Castro DG; Tokeshi L; Sampaio LA; Leite CC; Shavitt RG; Diniz JB; Busatto G; Norén G; Rasmussen SA; Miguel EC
    JAMA Psychiatry; 2014 Sep; 71(9):1066-76. PubMed ID: 25054836
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicting the therapeutic response to cognitive behavioural therapy in patients with pharmacoresistant obsessive-compulsive disorder.
    Prasko J; Raszka M; Adamcova K; Grambal A; Koprivova J; Kudrnovská H; Latalova K; Vyskocilová J
    Neuro Endocrinol Lett; 2009; 30(5):615-23. PubMed ID: 20035255
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
    Askari S; Mokhtari S; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
    BMC Psychiatry; 2022 Jan; 22(1):34. PubMed ID: 35022014
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Concurrent validity of the Yale-Brown Obsessive-Compulsive Scale-Symptom Checklist.
    Sulkowski ML; Storch EA; Geffken GR; Ricketts E; Murphy TK; Goodman WK
    J Clin Psychol; 2008 Dec; 64(12):1338-51. PubMed ID: 18942133
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Remission and Relapse Across Three Years in Pediatric Obsessive-Compulsive Disorder Following Evidence-Based Treatments.
    Ivarsson T; Jensen S; Højgaard DRMA; Hybel KA; Torp NC; Melin K; Nissen JB; Weidle B; Thomsen PH; Dahl K; Skarphedinsson G
    J Am Acad Child Adolesc Psychiatry; 2024 May; 63(5):519-527. PubMed ID: 38070870
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive symptom dimensions.
    Rosario-Campos MC; Miguel EC; Quatrano S; Chacon P; Ferrao Y; Findley D; Katsovich L; Scahill L; King RA; Woody SR; Tolin D; Hollander E; Kano Y; Leckman JF
    Mol Psychiatry; 2006 May; 11(5):495-504. PubMed ID: 16432526
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Benefits of stereotactic radiosurgical anterior capsulotomy for obsessive-compulsive disorder: a meta-analysis.
    Gupta R; Chen JW; Hughes NC; Hamo M; Jean-Baptiste S; Paulo DL; Chanbour H; Fan R; Ye F; Vadali A; Cmelak A; Bick SK
    J Neurosurg; 2024 Mar; ():1-12. PubMed ID: 38552242
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Validation of the Italian version of the Yale-Brown Obsessive Compulsive Scale-Second Edition (Y-BOCS-II) in a clinical sample.
    Melli G; Avallone E; Moulding R; Pinto A; Micheli E; Carraresi C
    Compr Psychiatry; 2015 Jul; 60():86-92. PubMed ID: 25842194
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results.
    Bareggi SR; Bianchi L; Cavallaro R; Gervasoni M; Siliprandi F; Bellodi L
    CNS Drugs; 2004; 18(5):329-35. PubMed ID: 15089116
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mindfulness-based cognitive therapy in obsessive-compulsive disorder: protocol of a randomized controlled trial.
    Külz AK; Landmann S; Cludius B; Hottenrott B; Rose N; Heidenreich T; Hertenstein E; Voderholzer U; Moritz S
    BMC Psychiatry; 2014 Nov; 14():314. PubMed ID: 25403813
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial.
    Ghobadian A; Mokhtari S; Shariati B; Kamalzadeh L; Shati M; Eftekhar Ardebili M; Yarahmadi M; Shalbafan M
    BMC Pharmacol Toxicol; 2022 Sep; 23(1):73. PubMed ID: 36167636
    [TBL] [Abstract][Full Text] [Related]  

  • 58. L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.
    Nematizadeh M; Ghorbanzadeh H; Moghaddam HS; Shalbafan M; Boroon M; Keshavarz-Akhlaghi AA; Akhondzadeh S
    Psychiatry Clin Neurosci; 2023 Sep; 77(9):478-485. PubMed ID: 37169515
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder.
    Saxena S; Winograd A; Dunkin JJ; Maidment K; Rosen R; Vapnik T; Tarlow G; Bystritsky A
    J Clin Psychiatry; 2001 Jan; 62(1):67-72; quiz 73. PubMed ID: 11235937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development and psychometric evaluation of the Yale-Brown Obsessive-Compulsive Scale--Second Edition.
    Storch EA; Rasmussen SA; Price LH; Larson MJ; Murphy TK; Goodman WK
    Psychol Assess; 2010 Jun; 22(2):223-32. PubMed ID: 20528050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.